Abstract:Abstract Background: The role of endoplasmic reticulum (ER) stress is profound in increasing malignant activity of neoplastic tumor cells and has been recently demonstrated to also increase immunosuppressive activity of tumor-associated macrophages (TAMs). Immunosuppressive TAM activity is thought to underly resistance to PD-1/PD-L1-targeted immune checkpoint inhibitors used for cancer therapy. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) is a rate-limiting enzyme central to the ER-stress response mechanism that transduces ER-stress signals in cells to regulate protein synthesis, cell death, and cell survival. We hypothesized that inhibition of PERK would improve responses to ICI therapy by reprogramming TAM from immunosuppressive to immunoactivating cells. Methods: To investigate if ER-stress underlies resistance to PD-1/PD-L1 targeted therapies, we utilized ex vivo assays to investigate ER-stress regulation of macrophage phenotype, and in vivo syngeneic murine models of melanoma growth, with HC-5404 (PERKi), a selective and potent first-in-human small molecule PERK inhibitor currently in a phase 1 clinical trial for solid tumors (NCT04834778). Results: Treatment with PERKi sensitized αPD-1/PD-L1 mAb-resistant melanoma tumors (Y1.7/YR1.7) to PD-1/PD-L1 blockade with concomitant increase in tumor infiltrating leukocytes, TH1- reprogrammed TAM, and cytotoxic CD8+ T cells. In addition to tumor microenvironment changes by PERKi, gene expression analysis confirmed reprograming of the tumor microenvironment, marked by a relative increase in TH1-associated genes and downregulation of TH2-associated genes when compared with untreated tumors. We utilized an ex vivo macrophage-splenocyte co-culture assay to depict macrophage dependent T cell suppression prevalent in tumors. This revealed that treating macrophages with PERKi prior to co-culturing with T cells or adding PERKi to the macrophage-T cell co-culture relieved macrophage dependent T cell suppression, illustrating a potential mechanism of therapeutic efficacy. We are now studying how ER-stress is regulated in TAMs and are focusing on identifying components of PERK-dependent cell signaling that increases the tumor promoting behavior of TAMs. Conclusions: The combination therapy targeting PERK and PD-1/PD-L1 signaling increased adaptive immune responses, reprogramed TAMs and reduced tumor growth kinetics. Results from these studies highlight a role for ER-stress signaling in TAMs to maintain an immunosuppressive tumor microenvironment and demonstrate the potential therapeutic strategy of PERK inhibition in αPD-1/PD-L1 resistant tumors. Citation Format: Sushil Kumar, Michael McCane, Jeremy Drees, Nandita Bose, Lisa Coussens. Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3247.

Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach

Abstract 3247: Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression

Enhancing anticancer activity of macrophages through rational drug combinations

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

Abstract 1679: Interference of PD-1 and PD-L1 Interaction with Small-Molecule Inhibitors Enhances the Efficacy of Tumor-Specific CTLs

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression

The Role of PD-1/PD-L1 Axis and Macrophage in the Progression and Treatment of Cancer

Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1

Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages